Novo Nordisk's Sickle Cell Drug Delivers as Buyback Program Advances

Novo Nordisk's oral sickle cell drug etavopivat met Phase 3 goals, cutting painful crises by 27%. The success pressures competitor Agios and diversifies Novo beyond GLP-1 drugs.

Novo Nordisk has secured a critical win beyond its core diabetes and obesity franchises. The Danish pharmaceutical giant announced on April 20 that its oral drug etavopivat successfully met both co-primary endpoints in the pivotal Phase 3 HIBISCUS trial for sickle cell disease, setting the stage for a regulatory filing next year.

The positive data had an immediate and severe impact on competitor Agios Pharmaceuticals, whose shares plunged 23%. Agios is developing a similar drug, mitapivat, which improved hemoglobin levels but failed to meet its primary endpoint of reducing painful vaso-occlusive crises (VOCs). Analysts at Truist Securities noted the results create "separation among the PK class candidates," though no head-to-head studies between the two drugs exist.

Trial Results and Competitive Landscape

In the randomized, double-blind 52-week study involving 385 patients aged 12 and older, etavopivat cut the annual rate of VOCs by 27% compared to placebo. The time to the first crisis extended from 20.9 weeks to 38.4 weeks. The hemoglobin response was even more pronounced, with 48.7% of patients on the treatment achieving an increase of more than 1 g/dL after 24 weeks, versus just 7.2% in the placebo group. Exploratory data also suggested a reduced need for blood transfusions.

This outcome contrasts with the recent fate of other contenders. Pfizer withdrew its drug Oxbryta globally in September 2024 due to safety concerns, following the failure of a core product it acquired in its $5.4 billion takeover of Global Blood Therapeutics. With approximately 8 million people living with sickle cell disease worldwide—including about 210,000 in the US and Europe combined—the market represents a concentrated target for a specialty drug.

Strategic Diversification and Financial Moves

For Novo Nordisk, etavopivat is a strategic pillar in its plan to diversify away from the GLP-1 segment. The drug, acquired through the $1.1 billion purchase of Forma Therapeutics in 2022, works by activating the pyruvate kinase-R enzyme in red blood cells—a novel mechanism with no currently approved medicines.

The company intends to submit its first applications for market approval in the second half of 2026. Etavopivat already holds Fast Track, Orphan Drug, and Rare Pediatric Disease designations in the US, along with an Orphan Drug designation from the European Commission.

Alongside the clinical update, Novo Nordisk provided a progress report on its share buyback initiative. Since the program began on February 4, 2026, the company has repurchased approximately 12.3 million B shares at an average price of 256.87 Danish kroner, for a total value of nearly 3.15 billion DKK. The overall program is authorized for up to 15 billion DKK over twelve months, with the current tranche targeting up to 3.8 billion DKK by early May.

Market Context and Outlook

The stock has shown resilience, trading around EUR 34.40—slightly above its 50-day moving average and marking a gain of about 12% from its late-March low for the year. Its Relative Strength Index below 25 indicates a technically oversold position. Nonetheless, the share price remains more than 25% below where it started the year and over 52% off its 52-week high.

This pressure reflects broader financial headwinds. Novo Nordisk has forecast a 5% to 13% decline in both sales and operating profit for 2026 at constant exchange rates. A successful launch of etavopivat, potentially reaching the market by 2027, would provide a new revenue stream in hematology and a buffer against ongoing pricing pressures in its core business.